<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03521570</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00100923</org_study_id>
    <secondary_id>NCI-2018-00064</secondary_id>
    <secondary_id>Winship4221-17</secondary_id>
    <nct_id>NCT03521570</nct_id>
  </id_info>
  <brief_title>Intensity-Modulated Radiation Therapy &amp; Nivolumab for Recurrent or Second Primary Head &amp; Neck Squamous Cell Cancer</brief_title>
  <official_title>Phase II Study of IMRT Re-Irradiation With Concurrent/Adjuvant Nivolumab in Patients With Locoregionally Recurrent or Second Primary Squamous Cell Cancer of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well intensity-modulated radiotherapy and nivolumab work&#xD;
      together in treating patients with head and neck squamous cell cancer that has come back.&#xD;
      Intensity-modulation radiation therapy uses varying intensities of radiation beams to kill&#xD;
      cancer cells and shrink tumors, thereby reducing the damage to nearby healthy tissue.&#xD;
      Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to&#xD;
      grow and spread. Giving intensity-modulated radiation therapy and nivolumab may work better&#xD;
      at treating head and neck squamous cell cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess the 1-year progression-free survival (PFS) for patients with recurrent or second&#xD;
      primary head and neck squamous cancer treated with intensity-modulated radiation therapy&#xD;
      (IMRT) re-irradiation with concurrent and adjuvant nivolumab.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate the 1-year (yr) overall survival (OS) of patients treated with re-irradiation and&#xD;
      nivolumab.&#xD;
&#xD;
      II. Evaluate patient quality of life (QOL).&#xD;
&#xD;
      III. Evaluate patterns of failure including local, regional and distant failure rates at 1&#xD;
      yr.&#xD;
&#xD;
      IV. Identify and estimate the incidence rate of acute and late toxicities associated with&#xD;
      combined re-irradiation and concurrent and adjuvant nivolumab.&#xD;
&#xD;
      TERTIARY OBJECTIVE:&#xD;
&#xD;
      I. To identify potential biomarkers related to clinical benefit to concurrent and adjuvant&#xD;
      nivolumab and re-irradiation in patients with recurrent or second primary (RSP) head and neck&#xD;
      squamous cell carcinoma (HNSCC).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive nivolumab intravenously (IV) over 30 minutes on weeks -2, 0, 2, 4, and 6 and&#xD;
      undergo IMRT once daily beginning on week 0 for up to 6-6.5 weeks. Beginning week 10,&#xD;
      patients receive nivolumab IV over 30 minutes every 4 weeks for up to 10 courses in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 2 years from the beginning&#xD;
      of radiation therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2018</start_date>
  <completion_date type="Anticipated">January 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 19, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 year progression-free survival (PFS)</measure>
    <time_frame>1 year from study start</time_frame>
    <description>95% confidence interval will be estimated by Kaplan-Meier method for all participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1 year overall survival (OS)</measure>
    <time_frame>1 year from study start</time_frame>
    <description>Will be assessed using Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern of failure</measure>
    <time_frame>1 year from study start</time_frame>
    <description>To evaluate patterns of failure as local, regional, or distant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute adverse events</measure>
    <time_frame>Up to 1 year from study start</time_frame>
    <description>Acute toxicities will be identified and their incidence rate estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of late adverse events</measure>
    <time_frame>2 years from study start</time_frame>
    <description>Late toxicities will be identified and their incidence rate estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>Up to 2 years from study start</time_frame>
    <description>The Functional Assessment of Cancer Therapy-Head and Neck (FACT-HN) Quality of Life (QOL) assessments will be performed at baseline, end of IMRT, and weeks 18, 30, 52, and 104. Paper or electronic questionnaires may be completed by the patient.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Recurrent Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (nivolumab, IMRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive nivolumab IV over 30 minutes on weeks -2, 0, 2, 4, and 6 and undergo IMRT once daily beginning on week 0 for up to 6-6.5 weeks. Beginning week 10, patients receive nivolumab IV over 30 minutes every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>Undergo intensity-modulated radiation therapy</description>
    <arm_group_label>Treatment (nivolumab, IMRT)</arm_group_label>
    <other_name>Intensity-Modulated Radiation Therapy</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (nivolumab, IMRT)</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>MDX-1106</other_name>
    <other_name>ONO-4538</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with recurrent squamous cell carcinoma or a second primary arising in a&#xD;
             previously irradiated field&#xD;
&#xD;
          -  Life expectancy of greater than 6 months&#xD;
&#xD;
          -  Patients cannot have distant metastases and have to be candidates for curative&#xD;
             re-irradiation&#xD;
&#xD;
          -  Patients with salivary gland tumors are excluded (patients with nasopharynx or&#xD;
             sinonasal cancers can participate)&#xD;
&#xD;
          -  Patients with unresectable disease are eligible&#xD;
&#xD;
          -  Patients who undergo surgical resection will be allowed regardless of human papilloma&#xD;
             virus (HPV) status provided they have one of the following criteria:&#xD;
&#xD;
               -  Positive margins on pathology&#xD;
&#xD;
               -  Evidence of extracapsular spread on nodal pathology&#xD;
&#xD;
               -  Gross residual disease on postoperative or simulation imaging&#xD;
&#xD;
               -  N2/3 disease&#xD;
&#xD;
               -  T3/4 disease&#xD;
&#xD;
               -  Multifocal perineural invasion and/or lymphovascular space invasion&#xD;
&#xD;
          -  The majority of the anticipated target volume (&gt; 50%) must have been previously&#xD;
             treated to ≥ 40 Gy; prior radiation therapy (RT) must have been completed &gt; 6 months&#xD;
             prior to initiation of IMRT reirradiation; if previous RT records are unavailable,&#xD;
             investigators can estimate the dose to previously treated tissues based on completion&#xD;
             notes or other treatment history&#xD;
&#xD;
          -  An Eastern Cooperative Oncology Group (ECOG) performance score 0-2&#xD;
&#xD;
          -  Granulocytes &gt; 1500/mm³&#xD;
&#xD;
          -  Platelets &gt; 100,000/mm³&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 mg/dl&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dl&#xD;
&#xD;
          -  No other concurrent invasive malignancies treated for the past year (localized&#xD;
             prostate cancer or early stage skin cancer are not exclusion criteria)&#xD;
&#xD;
          -  Patients with carotid artery involvement or encasement will be allowed provided they&#xD;
             have no symptoms related to carotid involvement&#xD;
&#xD;
          -  No prior exposure to immunotherapy agents&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any known factors that would pose a contraindication to receiving nivolumab&#xD;
&#xD;
          -  Recursive partitioning analysis (RPA) class III patients defined as those expected to&#xD;
             begin reirradiation within 2 years of first course of radiation therapy AND are&#xD;
             percutaneous endoscopic gastrostomy (PEG) dependent or have a tracheostomy (patients&#xD;
             who have undergone total laryngectomy are not excluded)&#xD;
&#xD;
          -  Patients with metastases&#xD;
&#xD;
          -  Prior treatment with a programmed cell death protein-1 (PD-1)/programmed death-ligand&#xD;
             1 (PD-L1) inhibitor&#xD;
&#xD;
          -  Female patients of childbearing potential must have a negative serum pregnancy test&#xD;
             within 7 days prior to enrollment&#xD;
&#xD;
          -  Patients with primary salivary gland cancers are excluded&#xD;
&#xD;
          -  Patients who have had chemotherapy or biological therapy within 4 weeks of&#xD;
             registration&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, autoimmune disease requiring systemic steroids, symptomatic congestive&#xD;
             heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements&#xD;
&#xD;
          -  Patients who are pregnant or breast-feeding&#xD;
&#xD;
          -  Patients with known active human immunodeficiency virus (HIV), hepatitis (hep) B, or&#xD;
             hep C infection&#xD;
&#xD;
          -  Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             10 mg daily prednisone equivalents) or other immunosuppressive medications within 14&#xD;
             days of study drug administration; inhaled or topical steroids and adrenal replacement&#xD;
             doses &gt; 10 mg daily prednisone equivalents are permitted in the absence of active&#xD;
             autoimmune disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nabil F. Saba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nabil F. Saba, MD</last_name>
    <phone>404-686-0239</phone>
    <email>nfsaba@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allyson Anderson</last_name>
      <phone>404-686-0239</phone>
      <email>allyson.anderson@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shraddha Dubal</last_name>
      <phone>404-686-3258</phone>
      <email>shraddha.dubal@emoryhealthcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nabil F. Saba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Davis</last_name>
      <phone>404-778-1805</phone>
      <email>erin.t.davis@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tanie Soji</last_name>
      <phone>404-778-4582</phone>
      <email>tanie.thambachan@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nabil F. Saba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shlomo A. Koyfman, MD</last_name>
      <email>KOYFMAS@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Allison Horner</last_name>
      <phone>216-445-6354</phone>
      <email>starka3@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Shlomo A. Koyfman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart J. Wong, MD</last_name>
      <phone>866-680-0505</phone>
      <email>swong@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Stuart J. Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 30, 2018</study_first_submitted>
  <study_first_submitted_qc>April 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Nabil F. Saba</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

